Core Viewpoint - Tevogen Bio Holdings Inc. is transitioning from a biotechnology innovator to a dynamic enterprise that integrates artificial intelligence into its operations, aiming to deliver impactful and affordable therapies through advanced science and technology [1][2]. Company Developments - Tevogen has validated its proprietary ExacTcell™ platform and completed a successful proof-of-concept clinical trial for its first product, while also establishing a drug discovery R&D center and working on a GMP cell manufacturing facility [2]. - The company has built a robust intellectual property portfolio and initiated one of the pioneering AI initiatives in the industry, maintaining a 74% insider equity ownership [2][7]. AI Integration - The launch of the AI-driven PredicTcell™ platform has significantly improved target discovery efficiency, supported by strategic partnerships with technology leaders like Microsoft and Databricks [3]. - Recent patent filings have further secured Tevogen's intellectual property in AI-driven predictive modeling, positioning the company at the forefront of innovation [3]. Financial Position - Tevogen is well-capitalized and has access to necessary funding to execute its growth strategy, including the accelerated development of Tevogen.AI [4]. - The company has observed drastic time reductions in target analysis, translating to potential savings of billions in drug development costs [7]. Corporate Structure - Tevogen's new headquarters, fully funded by the CEO, centralizes R&D and AI teams to enhance innovation [7].

Core Insights - Tevogen Bio Holdings Inc. reported a significant increase in institutional ownership of its common stock, with a 60% rise as of March 31, 2025, compared to December 31, 2024 [2] - Major contributors to this growth were Vanguard and BlackRock, which collectively increased their holdings by 151% [2] - A notable 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a strong influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a positive indicator of confidence in the company's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activities and collaborations with Microsoft and Databricks, which are aimed at developing targeted therapies for cancers and infectious diseases [3] - The company plans to establish its own GMP cell manufacturing facility, further supporting its growth trajectory [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing transparency and engagement with investors [3]

WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in nondilutive fundin ...

Core Insights - Tevogen Bio Holdings Inc. reported a 60% increase in institutional ownership of its common stock as of March 31, 2025, compared to December 31, 2024 [2] - Vanguard and BlackRock were the largest contributors to this growth, increasing their holdings by 151% [2] - 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a significant influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a sign of confidence in Tevogen's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activity and collaborations with Microsoft and Databricks [3] - The company plans to establish its own GMP cell manufacturing facility, which is expected to enhance its capabilities in developing targeted therapies for cancers and infectious diseases [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing monitoring of investor sentiment [3]

Core Insights - Tevogen Bio Holdings Inc. is expanding its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft and Databricks to develop the beta version of the PredicTcell model [1][2] - The new dataset being curated focuses on oncology and aims to enhance the accuracy of the existing model, which previously utilized a virology dataset [2] - The development phase is supported by a recently published international patent application that details novel machine learning systems for predicting immunologically active peptides, crucial for targeted cancer therapies [3] Company Developments - Tevogen.AI is leveraging the Databricks Data Intelligence Platform to improve its foundational AI model, particularly in the complex field of oncology [2][4] - The company is also exploring external market opportunities as a potential revenue source, which may include enhanced analytics and visualization tools for the PredicTcell model [7] Strategic Collaborations - The collaboration with Microsoft and Databricks is highlighted as a significant advantage in building the alpha version of the AI model, emphasizing the importance of high-quality datasets in drug discovery [4]

Core Viewpoint - Tevogen Bio Holdings Inc. is transitioning from a biotechnology innovator to a dynamic enterprise that integrates artificial intelligence into its operations, aiming to deliver impactful and affordable therapies through advanced science and technology [1][2]. Group 1: Company Developments - Tevogen has validated its proprietary ExacTcell™ platform and completed a successful proof-of-concept clinical trial for its first product, while also establishing a drug discovery R&D center and working on a GMP cell manufacturing facility [2]. - The company has launched its AI-driven PredicTcell™ platform, enhancing target discovery efficiency and forming strategic partnerships with technology leaders like Microsoft and Databricks [3]. - Tevogen has a robust intellectual property portfolio, with recent patent filings that secure its position in AI-driven predictive modeling [3]. Group 2: Financial Position and Growth Strategy - Tevogen is well-capitalized and has access to necessary funding to execute its growth strategy, including the development of Tevogen.AI [4]. - The company highlights a 74% insider equity ownership, reinforcing its long-term vision and commitment to its mission [2][7]. - The establishment of a new in-house cell therapy manufacturing facility is underway, which is expected to enhance operational capabilities [7]. Group 3: Innovation and Cost Efficiency - The collaboration with Microsoft and Databricks has led to a drastic reduction in target analysis time, potentially saving billions in drug development costs [7]. - The new headquarters, funded by the CEO, centralizes R&D and AI teams to accelerate innovation within the company [7].

Core Viewpoint - Tevogen Bio Holdings Inc. is set to receive $1 million in grant funding to enhance its artificial intelligence-driven drug discovery program, Tevogen.AI, as part of a larger grant agreement potentially totaling $10 million [1][2][6]. Funding Details - The new $1 million funding is part of a previously announced grant agreement with KRHP LLC, which includes an initial $2 million received in January 2025 and may allow for an additional $8 million [2][6]. - The total potential funding of $10 million is categorized as non-dilutive, meaning it will not dilute existing shareholders' equity [2][6]. Strategic Focus - The funding will be directed towards improving Tevogen.AI's capabilities, specifically in target discovery, development timelines, and treatment accessibility for large patient populations [2][3]. - The company emphasizes its commitment to operational efficiency and strategic fund deployment to maximize shareholder value and patient impact [3]. Leadership Statement - Dr. Ryan Saadi, Chairman and CEO of Tevogen, highlighted the grant as an endorsement of Tevogen.AI's potential to accelerate drug development, reduce costs, and enhance access to precision cell therapies [3].

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as ...

Core Insights - Tevogen Bio Holdings Inc. supports the White House's AI Action Plan, emphasizing the need for domain-specific standards and regulatory frameworks in healthcare AI [1][2] - The company has developed PredicTcell™, a machine learning model that accelerates immunotherapy research, potentially saving billions in drug development costs [2][3] - Tevogen aims to provide scalable and ethical solutions to enhance access to advanced therapeutics for all Americans, aligning with the government's focus on innovation and equity [3] Company Developments - Tevogen.AI's collaboration with Microsoft and Databricks has led to the creation of the alpha version of PredicTcell™, which significantly reduces the time for target analysis in immunotherapy [2] - The model's development reflects the AI Action Plan's goals for rapid scientific innovation and improved AI adoption in healthcare [2] Industry Context - The AI Action Plan highlights the importance of building trust and governance in healthcare AI, which is crucial for the industry's growth and regulatory compliance [1] - Tevogen's initiatives align with the federal government's strategy to leverage AI for enhancing healthcare delivery and reducing costs [3]

Core Viewpoint - Tevogen Bio Holdings Inc. has announced the publication of its international patent application for a machine learning-based technology aimed at identifying immunologically active peptides, which is crucial for developing targeted therapies for diseases like cancer and infections [1][2]. Group 1: Technology and Innovation - The patented technology utilizes machine learning algorithms, developed in collaboration with Microsoft and Databricks, to enhance the identification of peptides that interact strongly with the immune system [1]. - Traditional methods for identifying these peptides often overlook important genetic diversity factors, but Tevogen.AI's approach aims to address these limitations [2]. - The technology focuses on efficiently screening and ranking potential peptides based on their immunological activity and continuously refining predictions using real-world data [6]. Group 2: Strategic Goals - The company emphasizes the importance of leveraging artificial intelligence to accelerate discovery, shorten development timelines, and reduce costs in the context of personalized T cell therapies [2]. - The goal is to deliver commercially attractive and economically viable therapies for various diseases, including cancers and infectious diseases [2].